Under Armour, Inc. (UAA)

Under Armour's stock has been recovering from its lows, but it is still in a weak longer-term position. The price of $5.16 sits 5.36% above its 50-day average and 12.82% below its 200-day average, and the 200-day average is the nearest level above the price. The CleaRank rating is Sell, with a score of 40 out of 100, which is more cautious than the Hold consensus among Wall Street analysts. The main reasons are shrinking revenue, a loss on a GAAP basis, and a fall in the stock after the last two earnings reports that did not beat expectations on the way down. The stock is still a candidate for further analyst revisions, which is what investors are watching now.

Under Armour has beaten its EPS estimate in four of the last seven reports, yet the stock fell in the first session after three of those four beats. The August 7, 2026 report is the clearest case: adjusted EPS of $0.05 came in against an estimate of $0.02, a beat of 150.00%, and the share price still dropped 4.53% in the first session. The February 6, 2026 report showed the opposite pattern, with EPS of $0.09 against an estimate of -$0.01 and a 20.38% gain in the first session. Investors have therefore been reacting to something other than the headline EPS comparison, and the company's revenue and GAAP figures point to where that something lies.

The company's net profit margin is -9.80% and its return on equity is -28.67%, against a sector median of 12.4%. Its operating margin of 2.27% is positive, so the core business earns something before interest and other charges, but the net result is still a loss. Debt-to-equity of 0.93 adds to the pressure, because a shrinking top line leaves less room to carry that debt. Analysts expect revenue for the current fiscal year to shrink 4.9% to $4.7B, so there is no sign yet of a turn in sales.

Insiders recorded no sales in the last 18 months and seven open-market purchases worth $123.3M in total. That is a notable contrast with the analyst side, where Citigroup kept a Sell rating on May 13, 2026, and Barclays downgraded the stock to Underweight from Equal-Weight on August 11, 2026. UBS has kept its Buy rating three times in 2026, most recently on October 28, 2026, while Truist Securities kept its Hold rating on August 10, 2026. The sell-side is split and the insider record is one-directional, which is a mix investors will weigh differently.

At a price-to-sales ratio of 0.46, the stock trades 75.8% below the sector median P/S of 1.9. The price has also moved in a wide range: the 52-week high is $8.15 and the low is $4.13, and the stock sits at 26% of that range. Its 30-day typical daily move is 3.36%, and its beta against the S&P 500 is 1.60, so the price swings more than the market on most days. The low sales multiple reflects the shrinking revenue and the GAAP loss, so it is a discount for those problems rather than evidence of mispricing on its own.

The base case for the coming months is that UAA keeps trading between its 50-day average near $4.90 and its 200-day average near $5.92, with direction set by whether revenue stops shrinking. Analysts' median 12-month target is $6.00, which is 16.3% above the price, and the range runs from $4.00 to $12.00. The analysts' figures expect EPS for the current fiscal year to shrink 13.7% to $0.10 and then grow 90.1% to $0.20 in the following year, so profit recovery depends on the next year, not this one. The case would improve if revenue returns to growth and the price clears the 200-day average. It would worsen if the price loses the 50-day average and moves toward the 52-week low of $4.13. Analyst coverage is split, with 4 buy, 18 hold and 4 sell ratings, so the outcome is not settled.

Support sits at the 20-day EMA of $5.10, just below the price, which is the nearest level a decline would meet. Below it, the 50-day SMA at $4.90 is the next level to watch, and the 52-week low of $4.13 is the third and most significant floor, as it marks the lowest price of the past year.